Evaluation of KRAS and BRAF mutation rate in cholangiocarcinoma

Evaluation of KRAS and BRAF mutation rate in cholangiocarcinoma - Evaluation of KRAS and BRAF mutation rate in cholangiocarcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006626

Enrollment

300

Registered

2011-10-28

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cholangiocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically confirmed as being adenocarcinoma of biliary tract. 2) Operation or biopsy was performed in Tohoku University Hospital. 3) enough sliced section (4 micron meter/slice) can be offered for this study. 4) Age: 20 years or older at operation or biopsy

Exclusion criteria

Exclusion criteria: All patients who does not meet the key inclusion criteria above.

Design outcomes

Primary

Measure	Time frame
mutation rate of KRAS and BRAF	—

Countries

Japan

Contacts

Public ContactHiroki Hayashi

Tohoku University Hospital Hepato-Biliary Pancreatic Surgery

hiroki@surg1.med.tohoku.ac.jp022-717-7205

Outcome results